ROS1 and non-small cell lung carcinoma: Cai et al.’s study revealed that BA/F3 fusion NSCLC cells (harboring SLC34A2-ROS1) could activate ROS1-SHP2 signaling to elevate PD-L1 expression and mediate immunogenicity (95).